Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients.

Rello J, Krenn CG, Locker G, Pilger E, Madl C, Balica L, Dugernier T, Laterre PF, Spapen H, Depuydt P, Vincent JL, Bogár L, Szabó Z, Völgyes B, Máñez R, Cakar N, Ramazanoglu A, Topeli A, Mastruzzo MA, Jasovich A, Remolif CG, Del Carmen Soria L, Andresen Hernandez MA, Ruiz Balart C, Krémer I, Molnár Z, von Sonnenburg F, Lyons A, Joannidis M, Burgmann H, Welte T, Klingler A, Hochreiter R, Westritschnig K.

Crit Care. 2017 Feb 4;21(1):22. doi: 10.1186/s13054-017-1601-9.

2.

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 2 investigators.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097.

PMID:
21482568
3.

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.

Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S; CAPTIVATE Trial Group.

Am J Respir Crit Care Med. 2011 Jun 1;183(11):1561-8. doi: 10.1164/rccm.201007-1167OC. Epub 2011 Feb 4.

PMID:
21297074
4.

[Updated acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from the South American Working Group (ConsenSur II)].

Bantar C, Curcio D, Jasovich A, Bagnulo H, Arango A, Bavestrello L, Famiglietti A, García P, Lopardo G, Losanovscky M, Martínez E, Pedreira W, Piñeyro L, Remolif C, Rossi F, Varón F.

Rev Chilena Infectol. 2010 Jun;27 Suppl 1:S9-S38. doi: /S0716-10182010000400002. Epub 2010 Jul 26. Spanish.

5.

Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.

Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Reimnitz P, Bogner JR; STIC Study Group.

Infection. 2009 Oct;37(5):407-17. doi: 10.1007/s15010-009-8468-x. Epub 2009 Sep 18.

PMID:
19768381
6.

Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.

Sension M, Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, González-García J, Donnelly A, Phiri P, Ledesma E, McGrath D; 067 Study Group.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):153-62. doi: 10.1097/QAI.0b013e3181a5701c.

PMID:
19346966
7.

Endocarditis due to vancomycin-resistant Enterococcus raffinosus successfully treated with linezolid: case report and review of literature.

Jasovich A, Ganaha MC, Ebi C, García RD, Blanco MA, Lopardo H.

Rev Argent Microbiol. 2008 Oct-Dec;40(4):204-7. Review.

PMID:
19213241
8.

Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.

Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R; 308 Study Group.

Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61. doi: 10.1016/j.diagmicrobio.2008.09.001. Epub 2008 Nov 5.

PMID:
18990531
9.

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.

Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I.

Clin Ther. 2008 May;30(5):868-83. doi: 10.1016/j.clinthera.2008.04.019.

PMID:
18555934
10.

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.

Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R; 308 Study Group; 313 Study Group.

Diagn Microbiol Infect Dis. 2008 Jul;61(3):329-38. doi: 10.1016/j.diagmicrobio.2008.04.009. Epub 2008 May 27.

PMID:
18508226
11.

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC; MOTIV (MOxifloxacin Treatment IV) Study Group.

Clin Infect Dis. 2008 May 15;46(10):1499-509. doi: 10.1086/587519.

PMID:
18419482
12.

Review of pharmacokinetic, pharmacodynamic and clinical studies with a modern combination of amoxicillin/sulbactam.

Soutric J, Bantar C, Caruso N, Heguilén R, Casellas JM Jr, Casellas JM, Farinati A, Jasovich A, Arenoso H, Rodriguez M.

Chemotherapy. 2006;52(4):200-4. Epub 2006 May 24. Review.

PMID:
16720984
13.

Impact of the infectious disease team on the rationale for antibiotic usage: an expeditious intervention strategy which avoids limiting the physician's freedom.

Jasovich A, Curcio D, Caso Nuñez H, Fernandez F, Jetuchowitz V, Prieto S, Belloni C.

J Chemother. 2003 Aug;15(4):409-11. No abstract available.

PMID:
12962372
14.

Amoxicillin-sulbactam: A combination with a sound pharmacokinetic-pharmacodynamic basis.

Jasovich A.

Drugs Today (Barc). 2001 Mar;37(3):187-188. No abstract available.

PMID:
12783091
15.

Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur).

Bantar C, Bavestrello L, Curcio D, Jasovich A, Absi R, Bagnulo H, Famiglietti A, García P, Labarca J, Mera J, Pedreira W, Sader H, Thompson L, Wey S; South American Working Group ConsenSur Group.

J Chemother. 2002 Dec;14 Suppl 4:1-22.

PMID:
12680511
16.

Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American working group (ConsenSur).

Bantar C, Bavestrello L, Curcio D, Jasovich A, Absi R, Bagnulo H, Famiglietti A, García P, Labarca J, Mera J, Pedreira W, Sader H, Thompson L, Wey S; ConsenSur Group.

J Chemother. 2002 Dec;14(6):635-6. No abstract available.

PMID:
12583558
17.

Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model.

Jasovich A, Soutric J, Morera G, Mastruzzo M, Vesco E, Izaguirre M, Mobilia L, Prieto S, Franco D, Curcio D, Absi R, Larrateguy L, Bustos JL, Oliva ME, Arenoso H, Bantar C.

J Chemother. 2002 Dec;14(6):591-6.

PMID:
12583551
18.

A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults.

Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, Gesser RM; Protocol 021 Study Group.

Urology. 2002 Jul;60(1):16-22.

PMID:
12100914
19.

Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms.

Bantar C, Nicola F, Fernandez Canigia L, Arenoso HJ, Soutric J, Montoto M, Blanco M, Smayevsky J, Jasovich A.

J Chemother. 2001 Aug;13(4):402-6.

PMID:
11589483
20.

A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.

Bantar C, Nicola F, Fernandez Canigia L, Arenoso HJ, Soutric J, Montoto M, Blanco M, Smayevsky J, Jasovich A.

J Chemother. 2000 Jun;12(3):223-7.

PMID:
10877517

Supplemental Content

Loading ...
Support Center